Bio-Path Holdings EBIT

The latest EBIT for BPTH is $-2.1M as of June 2026. That compares with $-7.2M in the prior-year period — up 70.5% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Bio-Path Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, BPTH's EBIT moved from $-7.2M to $-2.1M — a 70.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bio-Path Holdings's operating scale or balance-sheet position.

Against Healthcare companies, BPTH currently prints $-2.1M for EBIT, while the sector average sits near $99B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Bio-Path Holdings's growth, margins, and balance sheet.

A EBIT figure of $-2.1M for BPTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting BPTH's EBIT ($-2.1M), review year-over-year change from $-7.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.